Compare Regeneron Pharmaceuticals Inc (REGN) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs BlackRock TCP Capital Corp — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.14B), while BlackRock TCP Capital Corp trades at $4.04 (market cap $337.71M). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 225.5× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (18.88%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and BlackRock TCP Capital Corp for 88 Days on average.
| REGN | TCPC | |
|---|---|---|
Market Cap | $76.14B | $337.71M |
Volume | 500,239 | 436,109 |
Sector | Health | Financials |
52-Week High | $852.03 | $6.20 |
52-Week Low | $557.73 | $3.13 |
Typical Hold Time | 107 Days | 88 Days |
Enterprise Value | $70.85B | $1.09B |
Dividend Yield | 0.51% | 18.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
TCPC trades at $3.94, down 1.25% with a bearish technical outlook. The company reported negative revenue and net income trends from 2024-2026, though recent Q2 2026 earnings beat expectations. A strategic portfolio sale of $523 million aims to reduce leverage and improve liquidity. Analyst sentiment is mixed with 30.77% buy ratings but predominantly hold recommendations.
TCPC faces significant fundamental challenges with declining revenue and negative profitability metrics. The ongoing strategic review and portfolio cleanup may offer long-term value, but investors should weigh the high dividend yield against persistent negative cash flow and earnings trends. Key risks include execution of the strategic review and broader private credit market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
